Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole

被引:145
作者
Arima, S [1 ]
Endo, Y [1 ]
Yaoita, H [1 ]
Omata, K [1 ]
Ogawa, S [1 ]
Tsunoda, K [1 ]
Abe, M [1 ]
Takeuchi, K [1 ]
Abe, K [1 ]
Ito, S [1 ]
机构
[1] Tohoku Univ, Sch Med, Dept Internal Med 2, Aoba Ku, Sendai, Miyagi 98077, Japan
关键词
endothelium; arachidonic acid; cytochrome P-450 epoxygenase; miconazole; glomerular hemodynamics;
D O I
10.1172/JCI119829
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 [基础医学];
摘要
Although angiotensin II type 2 (AT(2)) receptor has recently been cloned, its functional role is not well understood. We tested the hypothesis that selective activation of AT(2) receptor causes vasodilation in the preglomerular afferent arteriole (Af-Art), a vascular segment that accounts for most of the preglomerular resistance. We microperfused rabbit Af-Arts at 60 mmHg in vitro, and examined the effect of angiotensin II (Ang II; 10(-11)-10(-8) M) on the luminal diameter in the presence or absence of the Ang II type 1 receptor antagonist CV11974 (CV; 10(-8) M). Ang II was added to both the bath and lumen of preconstricted Af-Arts, Ang II further constricted Af-Arts without CV (by 74 +/- 7% over the preconstricted level at 10(-8) M; P < 0.01, n = 7). In contrast, in the presence of CV, Ang II caused dose-dependent dilation; Ang II at 10(-8) M increased the diameter by 29 +/- 2% (n = 7, P < 0.01). This dilation was completely abolished by pretreatment with an AT(2) receptor antagonist PD123319 (10(-7) M, n = 6), suggesting that activation of AT(2) receptor causes vasodilation in Af-Arts, The dilation was unaffected by inhibiting either nitric oxide synthase (n = 7) or cyclooxygenase (n = 7), however, it was abolished by either disrupting the endothelium (n = 10) or inhibiting the cytochrome P-450 pathway, particularly the synthesis of epoxyeicosatrienoic acids (EETs, n = 7), These results suggest that in the Af-Art activation of the AT(2) receptor may cause endothelium-dependent vasodilation via a cytochrome P-450 pathway, possibly by EETs.
引用
收藏
页码:2816 / 2823
页数:8
相关论文
共 59 条
[1]
20-HETE requires increased vascular tone to constrict rabbit afferent arterioles [J].
Arima, S ;
Omata, K ;
Ito, S ;
Tsunoda, K ;
Abe, K .
HYPERTENSION, 1996, 27 (03) :781-785
[2]
HIGH GLUCOSE AUGMENTS ANGIOTENSIN-II ACTION BY INHIBITING NO SYNTHESIS IN IN-VITRO MICROPERFUSED RABBIT AFFERENT ARTERIOLES [J].
ARIMA, S ;
ITO, S ;
OMATA, K ;
TAKEUCHI, K ;
ABE, K .
KIDNEY INTERNATIONAL, 1995, 48 (03) :683-689
[3]
ENDOTHELIAL AT(1)-MEDIATED RELEASE OF NITRIC-OXIDE DECREASES ANGIOTENSIN-II CONTRACTIONS IN RAT CAROTID-ARTERY [J].
BOULANGER, CM ;
CAPUTO, L ;
LEVY, BI .
HYPERTENSION, 1995, 26 (05) :752-757
[4]
AGONISTIC AND ANTAGONISTIC PROPERTIES OF ANGIOTENSIN ANALOGS AT THE AT2-RECEPTOR IN PC12W CELLS [J].
BRECHLER, V ;
JONES, PW ;
LEVENS, NR ;
DEGASPARO, M ;
BOTTARI, SP .
REGULATORY PEPTIDES, 1993, 44 (02) :207-213
[5]
Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors [J].
Campbell, WB ;
Gebremedhin, D ;
Pratt, PF ;
Harder, DR .
CIRCULATION RESEARCH, 1996, 78 (03) :415-423
[6]
RENAL CYTOCHROME-P-450-RELATED ARACHIDONATE METABOLISM IN RABBIT AORTIC COARCTATION [J].
CARROLL, MA ;
SCHWARTZMAN, M ;
BABA, M ;
MILLER, MJS ;
MCGIFF, JC .
AMERICAN JOURNAL OF PHYSIOLOGY, 1988, 255 (01) :F151-F157
[7]
CARROLL MA, 1992, J PHARMACOL EXP THER, V260, P104
[8]
IDENTIFICATION OF ANGIOTENSIN-II RECEPTOR SUBTYPES [J].
CHIU, AT ;
HERBLIN, WF ;
MCCALL, DE ;
ARDECKY, RJ ;
CARINI, DJ ;
DUNCIA, JV ;
PEASE, LJ ;
WONG, PC ;
WEXLER, RR ;
JOHNSON, AL ;
TIMMERMANS, PBMWM .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 165 (01) :196-203
[9]
EFFECT OF CYTOCHROME-P450 ARACHIDONATE METABOLITES ON ION-TRANSPORT IN RABBIT KIDNEY LOOP OF HENLE [J].
ESCALANTE, B ;
ERLIJ, D ;
FALCK, JR ;
MCGIFF, JC .
SCIENCE, 1991, 251 (4995) :799-802
[10]
CYTOCHROME P450-DEPENDENT EFFECTS OF BRADYKININ IN THE RAT-HEART [J].
FULTON, D ;
MAHBOUBI, K ;
MCGIFF, JC ;
QUILLEY, J .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 114 (01) :99-102